ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Stem Cell and Novel Neurotrophic Factors to Promote Functional Outcomes in Limb Transplantation

S. K. Salgar, J. Weiss, C. Phillips, E. Malin, V. Gorantla, J. Harding

Clinical Investigation, Madigan Army Medical Center, Tacoma, WA

Meeting: 2020 American Transplant Congress

Abstract number: D-235

Keywords: Growth factors, Rat, Stem cells

Session Information

Date: Saturday, May 30, 2020

Session Name: Poster Session D: VCA

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

Related Abstracts
  • Stem Cell and Granulocyte- Colony Stimulating Factor Therapies to Improve Functional Outcomes in Limb Transplantation
  • Mesenchymal Stem Cell Therapy To Promote Functional Recovery in a Limb Transplant Model

*Purpose: Recently, transplantation of hand and face has become a new clinical specialty. The objective of this study was to determine whether adult Mesenchymal Stem Cells (MSCs), Granulocyte-Colony Stimulating Factor (G-CSF) and/or Dihexa can promote limb transplant function.

*Methods: We used rat sciatic nerve transection-repair model. There were 10 experimental groups (n=6/group). Bone marrow derived syngeneic MSCs (2 million), G-CSF (50-100µg/kg), (Dihexa 2-4mg/kg) and/or Vehicle were administered locally via hydrogel at the site of nerve repair, i.v./i.p., and to gastrocnemius muscle.

*Results: Total sensory function was ~1.4, 1.7, 2.7 and 2.9 at 2, 4, 8 and 16 weeks post-nerve repair, respectively, on a scale of Grade 0-3 (0=No function; 3= Normal function) in all groups combined; peroneal nerve function recovered quickly by one week (~2.0) and sural nerve function recovered slowly by four weeks (~1.0). Motor function at 16 weeks post-nerve repair as determined by walking foot print grades 0-4 (0=no print; 4=heel plus 4-5 toe prints) was 3.0±0.9, 3.0±0.8, and 2.0±0.6 in MSC+G-CSF, MSC+Dihexa and MSC+vehicle groups with gastrocnemius injections, respectively; however, without gastrocnemius injection it was ~1.6. G-CSF or Dihexa injections to gastrocnemius significantly (P<0.05) improved motor function, mitigated muscle atrophy and reduced flexion contractures. MSCs expanded ex vivo were CD29+, CD90+, CD34-, CD31-, MHC Class I+, Class II- and multipotent. In a parallel study with tibial nerve repair we observed significant nerve regeneration/myelination with MSC therapy (n≥6).

*Conclusions: It appears, MSC, G-CSF and Dihexa are promising candidates for adjunct therapies to promote limb transplant function.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Salgar SK, Weiss J, Phillips C, Malin E, Gorantla V, Harding J. Stem Cell and Novel Neurotrophic Factors to Promote Functional Outcomes in Limb Transplantation [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/stem-cell-and-novel-neurotrophic-factors-to-promote-functional-outcomes-in-limb-transplantation/. Accessed February 28, 2021.

« Back to 2020 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.